- Home
- ARAY vs TLSA Comparison
ARAY vs TLSA Comparison
Compare ARAY & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- TLSA
- Stock Information
- Founded
- ARAY 1990
- TLSA 2013
- Country
- ARAY United States
- TLSA United Kingdom
- Employees
- ARAY N/A
- TLSA N/A
- Industry
- ARAY Medical/Dental Instruments
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- TLSA Health Care
- Exchange
- ARAY Nasdaq
- TLSA Nasdaq
- Market Cap
- ARAY 170.1M
- TLSA 187.0M
- IPO Year
- ARAY 2007
- TLSA 2000
- Fundamental
- Price
- ARAY $1.59
- TLSA $1.66
- Analyst Decision
- ARAY Strong Buy
- TLSA
- Analyst Count
- ARAY 1
- TLSA 0
- Target Price
- ARAY $5.00
- TLSA N/A
- AVG Volume (30 Days)
- ARAY 680.5K
- TLSA 325.5K
- Earning Date
- ARAY 11-05-2025
- TLSA 05-06-2025
- Dividend Yield
- ARAY N/A
- TLSA N/A
- EPS Growth
- ARAY N/A
- TLSA N/A
- EPS
- ARAY N/A
- TLSA N/A
- Revenue
- ARAY $458,505,000.00
- TLSA N/A
- Revenue This Year
- ARAY $5.84
- TLSA N/A
- Revenue Next Year
- ARAY $3.90
- TLSA N/A
- P/E Ratio
- ARAY N/A
- TLSA N/A
- Revenue Growth
- ARAY 2.68
- TLSA N/A
- 52 Week Low
- ARAY $1.14
- TLSA $0.63
- 52 Week High
- ARAY $2.95
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- ARAY 57.50
- TLSA 43.10
- Support Level
- ARAY $1.55
- TLSA $1.63
- Resistance Level
- ARAY $1.65
- TLSA $1.88
- Average True Range (ATR)
- ARAY 0.07
- TLSA 0.15
- MACD
- ARAY 0.00
- TLSA -0.01
- Stochastic Oscillator
- ARAY 65.00
- TLSA 38.46
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.